Compare Viatris Inc (VTRS) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs WD 40 Company — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while WD 40 Company trades at $199.54 (market cap $2.71B). The key difference: Viatris Inc is far larger — about 7× WD 40 Company's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| VTRS | WDFC | |
|---|---|---|
Market Cap | $19.09B | $2.71B |
Sector | Health | Technology |
52-Week High | $17.86 | $264.91 |
52-Week Low | $9.49 | $187.52 |
Enterprise Value | $31.21B | $2.76B |
Dividend Yield | 2.89% | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
WDFC trades at $201.73, down 2.81% today, with a bearish technical signal but strong fundamentals. Recent earnings show mixed results with a Q4 2025 miss but Q1 and Q2 2026 beats. The company maintains robust profitability with a 55.82% gross margin and 13.22% net margin. News highlights strong Q3 2026 performance and strategic growth initiatives including global expansion and digital transformation.
Outlook is cautiously optimistic with solid brand loyalty and growth potential, but risks include input cost pressures and valuation concerns. Analyst consensus is mixed with a 'Hold' majority. The stock's current price near support at $199 suggests potential stability if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
